Response of Iron Overload to Deferasirox in Rare Transfusion-Dependent Anaemias: Equivalent Effects on Serum Ferritin and Labile Plasma Iron for Haemolytic or Production Anaemias
Resource
EUROPEAN JOURNAL OF HAEMATOLOGY v.87 n.4 pp.338-348
Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Journal Volume
v.87
Journal Issue
n.4
Pages
338-348
Date Issued
2011
Date
2011
Author(s)
LIN, KAI-HSIN
Abstract
Objectives: It is widely assumed that, at matched transfusional iron- loading rates, responses to chelation therapy are similar, irrespective of the underlying condition. However, data are limited for rare transfusion- dependent anaemias, and it remains to be elucidated if response differs, depending on whether the anaemia has a primary haemolytic or production mechanism. Methods: The efficacy and safety of deferasirox (Exjade (R)) in rare transfusion-dependent anaemias were evaluated over 1 yr, with change in serum ferritin as the primary efficacy endpoint. Initial deferasirox doses were 10-30 mg/kg/d, depending on transfusion requirements; 34 patients had production anaemias, and 23 had haemolytic anaemias. Results : Patients with production anaemias or haemolytic anaemias had comparable transfusional iron-loading rates (0.31 vs. 0. 30 mL red blood cells/kg/d), mean deferasirox dosing (19.3 vs. 19.0 mg/kg/d) and baseline median serum ferritin (2926 vs. 2682 ng/mL). Baseline labile plasma iron (LPI) levels correlated significantly with the transfusional iron-loading rates and with serum ferritin levels in both cohorts. Reductions in median serum ferritin levels were initially faster in the production than the haemolytic anaemias, but at 1 yr, similar significant reductions of 940 and 617 ng/mL were attained, respectively (-26.0% overall). Mean LPI decreased significantly in patients with production (P < 0. 0001) and haemolytic (P = 0.037) anaemias after the first dose and was maintained at normal mean levels (< 0.4 mu m) subsequently. The most common drug- related, investigator- assessed adverse events were diarrhoea (n = 16) and nausea ( n = 12). Conclusions: At matched transfusional iron-loading rates, the responses of rare transfusion-dependent anaemias to deferasirox are similar at 1 yr, irrespective of the underlying pathogenic mechanism.
Subjects
rare anaemias
iron overload
iron chelation therapy
serum ferritin
safety
SDGs